Clinical Trials Logo
  1. Home
  2. Locally Advanced Gastric Cancer
  3. NCT03322969

Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy

Locally Advanced Gastric Cancer Clinical Trial

Official title:
Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy Versus Receiving the Original Chemotherapy in Locally Advanced Gastric Cancer: a Randomized Controlled Study

Clinical Trial Summary

For patients undergoing postoperative therapy for locally advanced gastric cancer after neoadjuvant chemotherapy, we assessed the utility of graded histologic regression of <50% as the criterion of treatment change. Sixty patients will be enrolled to randomize into two groups：receiving modified chemotherapy and receiving the original chemotherapy.

Clinical Trial Description

For patients undergoing postoperative therapy for locally advanced gastric cancer after neoadjuvant chemotherapy, we assessed the utility of graded histologic regression of <50% as the criterion of treatment change. Sixty patients will be enrolled to randomize into two groups：receiving modified chemotherapy and receiving the original chemotherapy. Overall survival and disease-free survival will be observed between two groups. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03322969
Study type Interventional
Source Peking Union Medical College Hospital
Contact Xiang Wang, Doctor
Phone 011-86-10-69151279
Email wangxiang5123@126.com
Status Recruiting
Phase Phase 2
Start date August 23, 2017
Completion date August 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05545436 - Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer Phase 2
Not yet recruiting NCT05524974 - Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes Phase 2
Active, not recruiting NCT03192735 - Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT03961373 - Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer Phase 3
Completed NCT02192983 - A Comparison of XELOX Regimen and EOX Regimen as Neoadjuvant Chemotherapy Regimen for Locally Advanced Gastric Cancer. N/A
Not yet recruiting NCT05610332 - Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes Phase 3
Recruiting NCT02855788 - Metronomic Chemotherapy in Advanced Gastric Cancer Phase 2
Not yet recruiting NCT02365896 - Comparison of Short Term Outcomes Between Totally Laparoscopic and Laparoscopy-Assisted Distal Gastrectomy With Billroth-II Reconstruction and D2 Lymphadenectomy for Locally Advanced Gastric Cancer N/A
Recruiting NCT05141747 - A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer. Phase 2
Active, not recruiting NCT06277453 - Effect of Adjuvant Chemotherapy Cycles on Patients With Node-negative Gastric Cancer Following Neoadjuvant Chemotherapy
Recruiting NCT05528367 - Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Phase 2
Recruiting NCT04792515 - Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer Phase 2
Active, not recruiting NCT06235164 - The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer
Recruiting NCT02302794 - A Multicenter Clinical Trial on Laparoscopic Gastric Cancer Surgery Compared With Open Surgery Phase 3